Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia

Hematological Oncology

Volumn 35, Issue 4, 2017, Pages 664-670

  Le Bris, Yannick ^a,b   Struski, Stéphanie ^a   Guièze, Romain ^c   Rouvellat, Caroline ^a   Prade, Naïs ^a   Troussard, Xavier ^d   Tournilhac, Olivier ^c   Béné, Marie C ^b   Delabesse, Eric ^a   Ysebaert, Loïc ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

CLL; complex karyotype; IGHV; TP53

Indexed keywords

ATM PROTEIN; CYCLOPHOSPHAMIDE; FLUDARABINE; MYELOID DIFFERENTIATION FACTOR 88; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PROTEIN; PROTEIN P53; RITUXIMAB; SF3B1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR MARKER;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK POPULATION; HUMAN; KARYOTYPE; KARYOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL ANALYSIS; TRISOMY 12; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; MORTALITY; MUTATION; PROGNOSIS; RECURRENT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84992463458     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2349     Document Type: Article

References (24)

1. Haferlach C, Dicker F, Schnittger S, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442–2451.
2. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108:3152–3160.
3. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117:3016–3024.
4. Strati P, Keating MJ, O'Brien SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014;99:1350–1355.
5. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720–724.
6. Jaglowski SM, Ruppert AS, Heerema NA, et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol. 2012;159:82–87.
7. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
8. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589–2597.
9. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121:1403–1412.
10. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123:2139–2147.
11. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365:2497–2506.
12. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105.
13. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
14. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645.
15. Mitelman F. An International System for Human Cytogenetic Nomenclature (ISCN): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S Karger B. 2009;
16. Chun K, Hagemeijer A, Iqbal A, Slovak ML. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: an International Working Group on MDS Cytogenetics Study. Leuk Res. 2010;34:160–165.
17. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V. (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854.
18. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. 2008;36: W503–W508.Web Server issue
19. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–3254.
20. Bo MD, Del Principe MI, Pozzo F, et al. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Ann Hematol. 2014;93:1765–1774.
21. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118:3051–3061.
22. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847.
23. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–1924.
24. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015;125:2062–2067.